Table 2.

Score of histopathological lesions found in the airways of untreated or resveratrol treated mice, intranasally infected with NTHi375.

		b Score (mean ± SD)
		Upper airways				Lung
Infecting NTHi strain	a Treatment	Secretion and erythrocytes in lumen	PMNs lumen	Hyperemia	PMNs lamina propria	Haemorrhage	Alveolar macrophages	Hyperemia	Bronchial-alveolar PMNs
NTHi375	Control untreated	1.7 ± 0.4	1.6 ± 0.2	1 ± 0.2	1.4 ± 0.2	0.2 ± 0.2	0.5 ± 0	0.7 ± 0.1	0.9 ± 0.1
NTHi375	RESV150	1 ± 0.3	c2.5 ± 0.2	0.8 ± 0.1	1 ± 0.2	0.1 ± 0.1	0.5 ± 0	0.8 ± 0.1	d0.3 ± 0.1

^aControl untreated animals were administered vehicle solution (PBS:DMSO, 1:1). RESV treated animals were administered three RESV doses (150 mg/kg) at 48, 24, and 1 h before infection and one RESV (150 mg/kg) dose at 6 hpi. Mice were euthanized at 12 hpi. ^bStatistical comparisons of mean values were performed using the two-tail t test. ^cLarger numbers of PMNs in the upper airways lumen of RESV treated than control untreated animals (p < 0.05) infected by NTHi375. ^dLower PMNs numbers at the bronchi and alveoli of mice treated with RESV, compared to controls (p =0.01) infected by NTHi375.